NSE: PVRINOX· MediaTurnaround · Aug 26Small cap

PVR Inox

Exhibition duopoly-of-one at book

Last close
₹1,190.10
29 Sept 2026 · reference
1D · 1M
−2.8% · −2.5%
price-only
Weight
1.5%
31 Jul 2026 · Aug rank 24
Thesis review
8 Sep 2026
Why We Own, p64
Coverage owner: Research (per book); latest results Q Jun-26Screener ↗Tijori ↗NSE ↗
Map

What must happen → what could break it → what we watch

Catalysts · 3
  • H2 FY27 (Oct-Dec 2026) festive slate plus bunched Q2/Q3 screen openings (~100 for FY27) - Q3FY27 results in Jan-2027 are the key print.
    C1
  • Zero net debt milestone targeted by end-FY27 (Mar-2027) enabling a return to dividends/higher ROCE toward pre-COVID levels.
    C2
  • Ormax/FICCI CY2026 box office: trend implies >Rs 15,000 cr full-year (record) if H2 holds.
    C3
Material risks · 3
  • Content dependence: no Rs 500 cr+ film in H1 CY26; a weak Diwali/H2 slate would stall admissions (FY26 Q4 admissions grew only 1.5% - growth was mostly pricing).
    R1
  • Advertising recovery lagging: FY26 ad revenue Rs 464 cr (+3.6%) is still below pre-COVID and management said brands need 'more proof of concept'; ad is the highest-margin line.
    R2
  • Regulatory/licensing delays bunch screen openings, and state-level ticket-price caps (Karnataka/Tamil Nadu precedents) or OTT window compression could hit ATP; interest coverage is still flagged 'low' by screener and ROE is only ~5%.
    R3
Live monitors
  • Valuation vs approved target
    No target stated
  • Latest reported quarter
    Q Jun-26
  • Results-driven thresholds
    Awaiting approved numbers

Catalysts and risks are the approved one-pager text in full; the register below adds owners and review dates. Monitors read from the price and fundamentals feeds.

Risks as a decision framework

Material risks

Risk register
#Risk (approved text)Owner · next review
01Content dependence: no Rs 500 cr+ film in H1 CY26; a weak Diwali/H2 slate would stall admissions (FY26 Q4 admissions grew only 1.5% - growth was mostly pricing).Research · post 2QFY27
02Advertising recovery lagging: FY26 ad revenue Rs 464 cr (+3.6%) is still below pre-COVID and management said brands need 'more proof of concept'; ad is the highest-margin line.Research · post 2QFY27
03Regulatory/licensing delays bunch screen openings, and state-level ticket-price caps (Karnataka/Tamil Nadu precedents) or OTT window compression could hit ATP; interest coverage is still flagged 'low' by screener and ROE is only ~5%.Research · post 2QFY27

Exposure mechanism, impact and mitigants are as written in the book. Leading indicators and numeric triggers not stated in the approved text remain research tasks rather than being invented.

Catalysts

Observable events

  • 01H2 FY27 (Oct-Dec 2026) festive slate plus bunched Q2/Q3 screen openings (~100 for FY27) - Q3FY27 results in Jan-2027 are the key print.
  • 02Zero net debt milestone targeted by end-FY27 (Mar-2027) enabling a return to dividends/higher ROCE toward pre-COVID levels.
  • 03Ormax/FICCI CY2026 box office: trend implies >Rs 15,000 cr full-year (record) if H2 holds.
Monitors

Live monitors from available data

  • ClearValuation exceeding the approved range: reference close 1,190 vs base target not stated.
  • DataLatest reported quarter in fundamentals: Q Jun-26. Results-driven monitors (growth below thesis threshold, margin, credit cost) need approved numeric thresholds; none in the book.
  • DataInput-cost and capital-allocation monitors require licensed commodity/filings feeds — not configured.